IFM Investors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $220M | Buy |
183,394
+18,709
| +11% | +$19.1M | 1.46% | 11 |
|
|
2026
Q1 | $151M | Buy |
164,685
+5,446
| +3% | +$5.52M | 1.26% | 11 |
|
|
2025
Q4 | $171M | Buy |
159,239
+1,667
| +1% | +$1.59M | 1.43% | 10 |
|
|
2025
Q3 | $114M | Sell |
157,572
-700
| -0.4% | -$521K | 1% | 12 |
|
|
2025
Q2 | $123M | Buy |
158,272
+5,972
| +4% | +$4.64M | 1.17% | 11 |
|
|
2025
Q1 | $126M | Sell |
152,300
-1,216
| -0.8% | -$1.01M | 1.36% | 12 |
|
|
2024
Q4 | $119M | Sell |
153,516
-13,800
| -8% | -$11.4M | 1.2% | 11 |
|
|
2024
Q3 | $148M | Buy |
167,316
+1,269
| +0.8% | +$1.14M | 1.42% | 10 |
|
|
2024
Q2 | $150M | Buy |
166,047
+2,292
| +1% | +$1.83M | 1.52% | 8 |
|
|
2024
Q1 | $127M | Sell |
163,755
-672
| -0.4% | -$478K | 1.39% | 8 |
|
|
2023
Q4 | $95.8M | Buy |
164,427
+382
| +0.2% | +$223K | 1.17% | 12 |
|
|
2023
Q3 | $88.1M | Buy |
164,045
+4,790
| +3% | +$2.47M | 1.16% | 12 |
|
|
2023
Q2 | $74.7M | Buy |
159,255
+8,201
| +5% | +$3.44M | 0.98% | 15 |
|
|
2023
Q1 | $51.9M | Buy |
151,054
+4,591
| +3% | +$1.55M | 0.79% | 20 |
|
|
2022
Q4 | $53.6M | Buy |
146,463
+6,537
| +5% | +$2.32M | 0.9% | 18 |
|
|
2022
Q3 | $45.2M | Buy |
139,926
+1,952
| +1% | +$618K | 0.82% | 18 |
|
|
2022
Q2 | $44.7M | Buy |
137,974
+9,201
| +7% | +$2.76M | 0.78% | 21 |
|
|
2022
Q1 | $36.9M | Buy |
128,773
+20,566
| +19% | +$5.29M | 0.57% | 30 |
|
|
2021
Q4 | $29.9M | Sell |
108,207
-1,398
| -1% | -$354K | 0.55% | 33 |
|
|
2021
Q3 | $25.3M | Sell |
109,605
-130
| -0.1% | -$32.1K | 0.52% | 38 |
|
|
2021
Q2 | $25.2M | Buy |
109,735
+15,510
| +16% | +$3.12M | 0.51% | 39 |
|
|
2021
Q1 | $17.6M | Buy |
94,225
+11,125
| +13% | +$2.18M | 0.47% | 42 |
|
|
2020
Q4 | $14M | Buy |
83,100
+11,661
| +16% | +$1.74M | 0.45% | 46 |
|
|
2020
Q3 | $10.6M | Buy |
71,439
+7,807
| +12% | +$1.21M | 0.44% | 49 |
|
|
2020
Q2 | $10.4M | Sell |
63,632
-23,244
| -27% | -$3.57M | 0.54% | 38 |
|
|
2020
Q1 | $12M | Sell |
86,876
-3,305
| -4% | -$454K | 0.54% | 40 |
|
|
2019
Q4 | $11.9M | Sell |
90,181
-4,909
| -5% | -$569K | 0.42% | 53 |
|
|
2019
Q3 | $10.6M | Buy |
95,090
+31,313
| +49% | +$3.49M | 0.39% | 53 |
|
|
2019
Q2 | $7.07M | Buy |
63,777
+557
| +0.9% | +$65.6K | 0.4% | 52 |
|
|
2019
Q1 | $8.2M | Buy |
63,220
+6,996
| +12% | +$851K | 0.53% | 38 |
|
|
2018
Q4 | $6.51M | Buy |
56,224
+4,735
| +9% | +$529K | 0.53% | 40 |
|
|
2018
Q3 | $5.53M | Buy |
51,489
+6,960
| +16% | +$696K | 0.42% | 49 |
|
|
2018
Q2 | $3.8M | Buy |
44,529
+13,637
| +44% | +$1.12M | 0.36% | 57 |
|
|
2018
Q1 | $2.39M | Buy |
30,892
+3,053
| +11% | +$246K | 0.34% | 63 |
|
|
2017
Q4 | $2.35M | Buy |
27,839
+20
| +0.1% | +$1.7K | 0.37% | 55 |
|
|
2017
Q3 | $2.38M | Buy |
27,819
+605
| +2% | +$49.6K | 0.4% | 52 |
|
|
2017
Q2 | $2.24M | Buy |
27,214
+7,062
| +35% | +$576K | 0.4% | 51 |
|
|
2017
Q1 | $1.7M | Buy |
20,152
+7,525
| +60% | +$603K | 0.43% | 51 |
|
|
2016
Q4 | $929K | Buy |
+12,627
| New | +$940K | 0.44% | 54 |
|
Other funds holding LLY
SC
ONB
GIM
IFM Investors's LLY Position: Q2 2026 in Review
IFM Investors increased its Eli Lilly (LLY) stake by 11% in Q2 2026, buying an estimated $19.1M and bringing the position to 183,394 shares worth $220M. The position accounts for 1.46% of the portfolio, ranked #11.
IFM Investors first reported a position in LLY in Q4 2016 and has held it in 39 quarters since. 1,424 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- IFM Investors held 183,394 shares of Eli Lilly worth $220M as of Q2 2026.
- IFM Investors bought 18,709 Eli Lilly shares in Q2 2026, an estimated $19.1M.
- Eli Lilly made up 1.46% of IFM Investors's portfolio in Q2 2026, its #11 holding.
- IFM Investors first reported a position in Eli Lilly in Q4 2016 and has held it in 39 quarters since.
- 1,424 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.